#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Internal Medicine / 2018 - 10

Some causes of poor adherence to long-term statin therapy and their solution

Česká verzia

Authors: Vladimír Soška 1,2,3;  Ondřej Kyselák 1
Authors place of work: Oddělení klinické biochemie FN U sv. Anny v Brně 1;  II. interní klinika LF MU a FN U sv. Anny v Brně 2;  Katedra laboratorních metod LF MU, Brno 3
Published in the journal: Vnitř Lék 2018; 64(10): 923-927
Category:

Summary

Statins are among the most important drugs in preventive cardiology because they greatly improve the prognosis of risk patients in both primary and secondary prevention of atherosclerotic cardiovascular disease. Adherence to long-term statin therapy is poor and decreases with the duration of statin use. A number of fake news about adverse effects of statins disseminated on the internet, such as damage of the brain, liver or kidney, contribute to worsening adherence. Statins therapy is sometimes unnecessary discontinued before planned surgery. The worse adherence to statin therapy may be also due to the fact that the patient does not know the connection between cholesterol lowering and improving his cardiovascular prognosis.

Key words:

adherence – brain – cholesterol – liver function – renal function – statins – surgery

Zdroje
  1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
  2. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 23(11): NP1-NP96. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487316653709>.
  3. Skoupá J. Dlouhodobá adherence ke kardiovaskulární farmakoterapii v České republice na příkladu amlodipinu a atorvastatinu. Kapitoly z kardiologie 2011; 3(2): 63–67. Dostupné z WWW: <https://www.tribune.cz/clanek/23155-dlouhodoba-adherence-ke-kardiovaskularni-farmakoterapii-v-ceske-republice-na-prikladu-amlodipinu-a-atorvastatinu>.
  4. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama 2002; 288(4): 462–467.
  5. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2940–2948. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht295>.
  6. Soška V, Kyselák O. Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny? Vnitř Lék 2017; 63(10): 663–666.
  7. Schouten O, Kertai MD, Bax JJ et al. Safety of Perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005; 95(5): 658–660. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2004.10.046>.
  8. Xia J, Qu Y, Yin C et al. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery. Cardiology 2015; 131(1): 30–37. Dostupné z DOI: <http://dx.doi.org/10.1159/000371872>.
  9. Lindenauer PK, Pekow P, Wang K et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291(17): 2092–2099. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.291.17.2092>.
  10. Paraskevas KI, Liapis CD, Hamilton G et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32(3): 286–293. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejvs.2006.03.009>.
  11. Sanders RD, Nicholson A, Lewis SR et al. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. Cochrane Database Syst Rev 2013; (7): CD009971. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD009971.pub2>.
  12. McGirt MJ, Perler BA, Brooke BS et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005; 42(5): 829–836; discussion 836–827. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jvs.2005.08.039>.
  13. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: The effects of statins. Am J Kidney Dis 2002; 40(3): 638–643. Dostupné z DOI: <http://dx.doi.org/10.1053/ajkd.2002.34927>.
  14. Wenke K, Meiser B, Thiery J et al. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz 2005; 30(5): 431–432. Dostupné z DOI: <http://dx.doi.org/10.1007/s00059–005–2685–6>.
  15. Johnson BA, Iacono AT, Zeevi A et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167(9): 1271–1278. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.200205–410OC>.
  16. Ward RP, Leeper NJ, Kirkpatrick JN et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104(3): 264–268. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2004.10.030>.
  17. Sai C, Li J, Yingbin X et al. Atorvastatin Prevents Postoperative Atrial Fibrillation for Patients undergoing Cardiac Surgery. Hellenic J Cardiol 2018: pii: S1109–9666(17)30450–5. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hjc.2017.12.012>.
  18. de Waal BA, Buise MP, van Zundert AA. Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery: a review. Br J Anaesth 2015; 114: 44–52. Dostupné z DOI: <http://dx.doi.org/10.1093/bja/aeu295>.
  19. An JH, Shi FW, Liu S et al. Preoperative statins as modifiers of cardiac and inflammatory outcomes following coronary artery bypass graft surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 2017; 25(6): 958–965. Dostupné z DOI: <http://dx.doi.org/10.1093/icvts/ivx172>.
  20. Fransgaard T, Thygesen LC, Gogenur I. Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer. Int J Colorectal Dis 2018; 33(2): 199–207. Dostupné z DOI: <http://dx.doi.org/10.1007/s00384–017–2947–9>.
  21. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(1): 3–46.
  22. Tziomalos K, Athyros VG, Paschos P et al. Nonalcoholic fatty liver disease and statins. Metabolism 2015; 64(10): 1215–1223. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2015.07.003>.
  23. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274–285. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2036.2011.04724.x>.
  24. Piepoli MF, Hoes AW, Agewall S et al. [Authors/Task Force Members]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207–274. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.037>.
  25. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376(9756): 1916–1922. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61272-X>.
  26. Tikkanen MJ, Fayyad R, Faergeman O et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168(4): 3846–3852. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2013.06.024>.
  27. Athyros VG, Alexandrides TK, Bilianou H et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17–32. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2017.02.014>.
  28. Del Ben M, Baratta F, Polimeni L et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2017; 27(2): 161–167. Dostupné z DOI: <http://dx.doi.org/10.1016/j.numecd.2016.09.011>.
  29. Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews 2014; (1): CD005019. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD005019.pub4>.
  30. Barylski M, Nikfar S, Mikhailidis DP et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy – a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35–44. Dostupné z DOI: <http://dx.doi.org/10.1016/j.phrs.2013.03.007>.
  31. LipFix (atorvastatin). Souhrn údajů o přípravku. SÚKL 2016; sp.zn.sukls96124/2016. Dostupné z WWW: <http://sukl.cz>.
  32. Qin X, Dong H, Fang K et al. The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis. Diabetes Metab Res Rev 2017; 33(6): e2901. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2901>.
  33. Zhang Z, Wu P, Zhang J et al. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74–83. Dostupné z DOI: <http://dx.doi.org/10.1016/j.phrs.2016.01.005>.
  34. Geng Q, Ren J, Song J et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol 2014; 114(4): 562–570. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2014.05.033>.
  35. Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 2015; 6(4): 254–264. Dostupné z DOI: <http://dx.doi.org/10.1007/s13238–014–0131–3>.
  36. Olsson AG, Angelin B, Assmann G et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med 2017; 281(6): 534–553. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.12614>.
  37. McFarland AJ, Anoopkumar-Dukie S, Arora DS et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci 2014; 15(11): 20607–20637. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms151120607>.
  38. Karam JG, Loney-Hutchinson L et al. [Stroke Prevetion by Aggressive Reduction in Cholestrol Levels Investigators]. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. J Cardiometab Syndr 2008; 3(1): 68–69.
  39. Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson’s disease: A meta-analysis. Behav Brain Res 2016; 309: 29–34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbr.2016.04.046>.
  40. Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A et al. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis 2017; 32(4): 949–965. Dostupné z DOI: <http://dx.doi.org/10.1007/s11011–017–0021–5>.
  41. Geifman N, Brinton RD, Kennedy RE et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther 2017; 9(1): 10. Dostupné z DOI: <http://dx.doi.org/10.1186/s13195–017–0237-y>.
  42. Swiger KJ, Manalac RJ, Blumenthal RS et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013; 88(11): 1213–1221. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2013.07.013>.
  43. Parsaik AK, Singh B, Murad MH et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160: 62–67. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jad.2013.11.026>.
  44. Salagre E, Fernandes BS, Dodd S et al. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord 2016; 200: 235–242. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jad.2016.04.047>.
Štítky
Diabetology Endocrinology Internal medicine
Článek Is functional dyspepsia really that frequent?
Článek Does the time from symptoms onset to treatment impact further development of vein thrombosis in the leg?
Článek Transient elastography – role in the assessment of the liver disease development
Článek Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management
Článek Obstructive sleep apnea and dyslipidemia
Článek CD38 targeted treatment for multiple myeloma
Článek Fatty pancreas disease: clinical impact
Článek Treatment of polycythemia vera
Článek Weber-Christian disease: a case report
Článek Multiple neuroendocrine tumor of the small bowel: a case report and a review of literature
Článok vyšiel v časopise

Internal Medicine

Číslo 10
2018 Číslo 10
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#